Complete Rescue of Lipoprotein Lipase–Deficient Mice by Somatic Gene Transfer of the Naturally Occurring LPLS447XBeneficial Mutation

Abstract

The naturally occurring human lipoprotein lipase S447X variant (LPL S447X) exemplifies a gain-of function mutation with significant benefits including decreased plasma triglycerides (TG), increased high-density lipoprotein (HDL) cholesterol, and reduced risk of coronary artery disease. The S447X variant may be associated with higher LPL catalytic activity; however, in vitro data supporting this hypothesis are contradictory. We wanted to investigate the in vivo mechanism by which the LPL S447X variant improves the lipid profile of S447X carriers. We conducted a functional assessment of human LPL S447X compared with LPL WT in mice. LPL variants were compared in the absence of endogenous mouse LPL in newborn LPL−/−mice by adenoviral-mediated gene transfer. LPL−/−mice normally exhibit severe hypertriglyceridemia and die within 48 hours of birth. LPL WT gene transfer prolonged the survival of mice up to 21 days. In contrast, LPL S447X completely rescued 95% of the mice to adulthood and increased LPL catalytic activity in postheparin plasma 2.1-fold compared with LPL WT at day 3 (P=0.003). LPL S447X also reduced plasma TG 99% from baseline (P<0.001), 2-fold more than LPL WT, (P<0.01) and increased plasma HDL cholesterol 2.9-fold higher than LPL WT(P<0.01). These data provide in vivo evidence that the increased catalytic activity of LPL S447X improves plasma TG clearance and increases the HDL cholesterol pool compared with LPL WT.